Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of MDI-2517 in Healthy Volunteers
NCT06453824Phase 1Completed
- Sponsor
- MDI Therapeutics
- Start
- May 2024
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MDI-2517 in systemic sclerosis (SSc) and interstitial lung disease (ILD) (8 cohorts), sponsored by MDI Therapeutics. Primary endpoint: Incidence of treatment emergent adverse events at 5 days. Started May 2024; status: completed.
02
Drugs
MDI-2517
03
Conditions
systemic sclerosis (SSc)interstitial lung disease (ILD)
Beyond the preview
Go deeper on NCT06453824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06453824.